• From mRNA to Cure

    By analyzing RNA we can detect disease, monitor health, and design Next Generation Cures.

     

    Our OneRNA platform enables repurposing existing drugs even on an individual patient basis and the development of novel RNA therapeutics e.g. RNA vaccines or CRISPR to develop Next Generation Cures.

    ARE YOU A DOCTOR OR A PATIENT ?

    Looking for better treatment options ? Our OneRNA Platform enables repurposing existing drugs on an individual patient basis

    ARE YOU DEVELOPING CURES?

    The OneRNA Platform makes the companion diagnostic into an algorithm

  • RNA Diagnostics

    By analyzing RNA we can monitor health, detect disease and design next generation cures
     

    DNA is not your fate. RNA is coding for proteins and proteins are targets for drugs, today RNA is directly a target for drugs and a drug itself. We are experts in analyzing RNA using PCR and Next Generation Sequencing to identify COVID-19 as well as better cancer treatments

    COVID-19 is an RNA Virus

    Analyzing the RNA from the virus in upper respiratory samples is the only way to detect an active infection. Our PCR assay is a real-time RT-PCR intended for the qualitative detection of RNA from the SARS-CoV-2 in saliva or nasopharyngeal swabs also in asymptomatic individuals

    OneRNA® for treatment selection in cancer

    DNA is not your fate. RNA codes for proteins and proteins are targets for drugs, furthermore today RNA is directly a target for drugs and a drug itself. We coded all that information into our OneRNA® platform and initiated 3 clinical studies to produce supporting data.

  • WHO WE ARE

    Experienced Management Team with Startup RNA

    Gitte Pedersen

    CEO and co-founder

    Gitte Pedersen, CEO is a former executive at NovoZymes, the world’s largest enzyme manufacturer. She has advised the Danish Government and early stage biotech companies regarding their corporate development in the US

     

    Follow at DNABARCODE

    Morten Pedersen

    CSO and cofounder

    Morten Pedersen, CTO and co-founder holds a Ph.D in genomics. He has a very strong innovation track record with multiple key patents in genomics. Morten is the inventor of Genomic Expression’s sample prep technologies
     

    Jesper Zeuthen

    VP Oncology research

    Jesper Zeuthen, CMO, is the co-founder of GeneMap and Topotarget (both had IPOs), and prior to that he established one of the laboratories that became the Danish Cancer Society.

    Bill Southworth

    VP of Data

    Bill Southworth, VP Data, MIT, creator of products. Been CEO and Vice President of Engineering and Marketing for public and private companies. Coder at heart

  • What our Customers say

    We work with corporations and governments to enable safe reopening our economy

    Laura Dinsmore, President and CEO

    Quadrant Health Strategies, Inc.

    "We highly value our collaboration with Genomic Expression. We have worked with them since they launched COVID19 testing and have been impressed with their turnaround time and extraordinary customer service, consistently stepping up, often on short notice"

     

    Mike Horrocks, CEO

    EREMA North America, Inc.

    " Access to rapid and accurate COVID19 testing for our employees is critical in allowing us to keep our facility open and to support our customers. It allows our employees to be confident in the work environment . Genomic Expressions ease of use, turnaround time, support and service has been essential in helping to reduce the risks in continuing our business model "

     

  • WHO'S TALKING ABOUT US

    We have been featured in Forbes twice, GEN, GenomeWeb and MedWatch. Our investors include Biogen founders, Impact Investors such as Investor Circle, the largest impact investment angel groups in the world, Pipeline Angels and a family office; Centurion Holding in New York.

     

    We are a Springboard alum company and among the 500 women-owned technology companies they have supported. Genomic Expression came in #2 in the Women’s Founders Pitch event in LA, was in the top 10 companies to pitch for Sir Richard Branson (Virgin Airlines) Extreme Tech Challenge, and invited to dinner with Branson on Necker’s Island, selected into the top 5 diagnostic companies at the Molecular Tri-Conference, finalist in Top 100 Red Herring and top 50 Global Medtech innovator.

     

    COVID19 is an RNA virus and we decided to participate in providing solutions and pivoted into COVID19 testing first by validating our own PCR test securing supply chain and filing our own EUA with the FDA and then by invented new chemistry that enables massive scaling of COVID19 testing using existing sequencing lab equipment. That landed us into the semi-finals of the XPRIZE for Rapid COVID19 testing and Blue Cross Blue Shields GuideWell finals. Latest we have proven we can use our unique chemistry to pool many samples which could further reduce cost. Finally we signed a licensing agreement with Yale to move the test into saliva which enables self testing that reduces risk to healthcare providers and individuals as well. Using Telehealth we can provide access to COVID19 testing in remote underserved areas and provide testing without the need to travel.

     

    This is our founder story:

  • Articles, Grants, Investors and Customers

    These are our supporters, funders and customers

    Grant 

    Genome Danmark

    Article 2011

    Interview 2014

    Feature Article 2014

    Accelerator

    Impact Investor

    Investor

    Impact Investor

    #2 at WFN

    Top 5 Mol Tri Conf.

    Top 10 XTC

    Top 100 Red Herring

    Horizon2020 grant

    Eurostars Grant

    Collaborator

    Winner of Owlers 2016 HOT in New York Award!

    MedTech Innovator Top 50

    Winner of the Lyfebulb-Helsinn Award

    Winner of the EIC Lifescience Award

    Featured in Forbes

    Won EUTop50 and invited to present at the European Parliament

    Presented at GSTIC addressing the UN sustainability goals in health

    Finals of the Blue Cross Blue Shields GuideWell competition for novel COVID19 solutions

    In the semi-finals of the XPRIZE for Rapid Covid Testing - $6 million dollar, 6-month competition to develop faster, cheaper, and easier to COVID-19 testing methods at scale.

    XPrize Semifinalist Targets 300 Million Tests Per Day With Scalable COVID Self-Test

  • WANT TO LEARN MORE ?

    DISCLAIMER

    The information contained in our website is for general reference only, and should not be relied upon for any medical decision, or as a recommendation for any course of medical treatment. By 'opting-in' to our website, you understand we are not undertaking any responsibility to provide you with medical advice of any kind or character. There is no representation as to the accuracy or completeness of the information on our website, and we have no obligation to update or correct any posted information.

  • YOU + SOCIAL MEDIA

    = SOCIAL IMPACT

    You're awesome. Let's talk.

    100 Cummings Center, Suite 451C. Beverly, MA  01915
All Posts
×